PDCD1 and neoplasm: Importantly, the rationale of our proposed anti-PD-1 strategy does not depend on tumor PD-L1 expression, since anti-PD-1 is for ex vivo treatment aiming to enhance the cytotoxicity of T lymphocytes for potential T cell–based therapies.